Cereno Scientific’s main partner is Galenica AB. In January 2016, a collaboration began with Galenica to jointly develop a unique formulation of Cereno Scientific’s drug candidate, CS1.
The goal is to optimize the clinical effect of CS1 and to create a more favorable commercial position.
Galenica is based in Medeon in Malmö and was founded in 1999. Galenica is a development company with a focus on the formulation, manufacture and quality control of medicines. Today the company has about 45 employees and has activities involving the development of drugs both on its own and on behalf of clients. The Company has also entered into smaller partnerships with GU Ventures and Synergon AB.